Trials / Completed
CompletedNCT02833883
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer
A Phase 1b Study of Enzalutamide Plus CC-115 in Men With Castration-Resistant Prostate Cancer (CRPC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study to define the good and/or bad effects of the combination of enzalutamide and CC-115 in patients with castration-resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | |
| DRUG | CC-115 |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2023-01-13
- Completion
- 2023-01-13
- First posted
- 2016-07-14
- Last updated
- 2023-01-19
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02833883. Inclusion in this directory is not an endorsement.